Weight-Related Health Conditions : Conditions such as high blood pressure, type 2 diabetes, or sleep apnea can make you a strong candidate for GLP-1 therapy
Subsequent case reports have documented similar concerning events, including the Gulak and Murphy series describing a 70-year-old male who regurgitated large-volume particulate contents during laryngoscopy two days after semaglutide cessation [5]
Regarding CV safety, semaglutide 14 mg was non-inferior to placebo based on time from randomization to first EAC-confirmed MACE indicating no increase in risk in the occurrence of MACE with semaglutide compared to placebo
1 2 Toft-Nielsen MB, Madsbad S, Holst JJ (August 2001)
When verifying, ask specifically about obesity treatment benefits, GLP-1 medication coverage, BMI eligibility requirements, prior authorization requirements, and your current deductible and copay structure
However, the lack of quality control in compounded medications raises concerns about potential impurities or incorrect dosages